Formation Bio @formationbio

Tune in around 3:40pm EST to hear @BenjamineYLiu on @tbpn!

TBPN @tbpn

8 hours ago

Happy Wednesday. On today's show: - @markgurman (Bloomberg) - @zac_rash (Coco Robotics) - @BenjamineYLiu (Formation Bio) - @AmiramShachar (Upwind) - @zjasper (Hyperbolic) See you on the stream.

3 5 16 9K 2

Most AI drug development firms are focused on discovery. AI biotech Formation Bio is betting the real bottleneck is clinical trials. With a new $600 million fund to buy or license potential drugs that have stalled out, the startup now hopes to prove that it’s right. Read more: forbes.com/sites/innovati… 📸: Guerin Blask for Forbes

Learn more about our new $600M Formation Bio Drug Development Accelerator Fund here.

Ben Liu @BenjamineYLiu

11 hours ago

Today we’re announcing the $600M Formation Bio Drug Development Accelerator Fund. @lintaho and I started @formationbio because we believed the biggest bottleneck in bringing new medicines to patients wasn’t drug discovery, but drug development. As AI dramatically accelerates

63 67 682 128K 322

(3/3) Phyla aggregates 90 tools across 27 biomedical sources and ties every single claim to a checkable citation. When asked a plain language question, Phyla pulls the gene record, checks clinical precedent, computes tissue-specific expression, and runs mechanistic analysis over the results — returning an answer with every claim traced to a source. Here’s how we built it, and how it’s used at Formation: formation.bio/blog/phyla

(2/3) In an audit of claims, Phyla led on every target-disease pair. 92% of Phyla’s claims were fully backed by the source it cited, vs. 80% (Claude Science) and 67% (GPT-Rosalind).

(1/3) Phyla is Formation Bio’s context layer for causal biology. We benchmarked it against Claude Science and GPT-Rosalind on writing full research dossiers for 7 drug target–disease pairs, and the results are in. 99.7% of Phyla’s statements carried a citation, compared to Claude Science: 87% (Claude Science) and 86% (GPT-Rosalind). Phyla never dropped below 99.3% on any pair.

Phyla aggregates 90 tools across 27 biomedical sources and ties every single claim to a checkable citation. Benchmarked against two other frontier AI life-science platforms, writing full research dossiers across 7 target–disease pairs: 99.7% of Phyla’s statements carried a citation (vs. 87% and 86%), and 92% of its claims were fully backed by the cited source (vs. 80% and 67%). See how we built it, and how it’s being used at Formation: formation.bio/blog/phyla

benjamineliu.com/p/uneven-front…

“As a company in the era of AI, you should have a thesis for what predictions will happen first, what will happen last, and make sure your company strategy absorbs this as a net tailwind versus a headwind.” Our thesis: AI will improve drug discovery first, toxicity next, and clinical efficacy last. Our CEO @BenjamineYLiu explores this in his Uneven Frontiers essay – link in comments.

Formation Bio made #7 on @FastCompany's Best Workplaces for Innovators 2026. This piece highlights one of our internal systems: ARK (AI-ready Repository of Knowledge), our in-house AI platform that connects all internal systems and data across the company. Full write-up here: fastcompany.com/91591991/forma… Our open roles: formation.bio/careers Learn more about ARK: formation.bio/blog/ark-mcp-g…

Proud to be selected as #7 on @FastCompany's 2026 100 Best Workplaces for Innovators, plus as a winner on the Biotech, Healthcare & Life Sciences list. Find us on the full list: fastcompany.com/best-workplace… We're hiring across New York and Boston now: formation.bio/careers

@BenjamineYLiu @LanceGlinn @NYSE Spotify: open.spotify.com/episode/60l2kZ… Youtube: youtube.com/watch?v=DaN84y…

Our CEO @BenjamineYLiu recently sat down with @LanceGlinn on @NYSE's Inside the ICE House to talk about how and why Formation Bio is tackling the drug development bottleneck, a problem that is only set to grow as the number of drugs at the top of the funnel increases. Links to listen in comments:

NYSE 🏛 @NYSE

2 months ago

Hear from @formationbio co-founder & CEO Ben Liu on @ICEHousePodcast where he talks about... - Bottleneck's slowing down drug development - AI's impact on drug discovery - Bringing new medicines to patients Spotify: open.spotify.com/episode/60l2kZ… YouTube: youtu.be/DaN84yEwBvU?si…

8 7 20 13K 3

"In a world of drug discovery abundance, the scarce capability is no longer making drugs, but rather, knowing which drugs are worth developing." @BenjamineYLiu, co-founder and CEO of Formation Bio, explains how AI will transform the economics of the pharma industry - link in replies

What drew Mike Ehlers, our new Chief Scientific Officer and Head of R&D, to Formation Bio? Hear it in his own words. More on Mike’s life outside the lab in today’s @statnews executive moves column: statnews.com/pharmalot/2026…

In his latest blog, our Principal Engineer Kenny Peng revisits the Unix philosophy (do one thing well, compose freely, shared interfaces) as a blueprint for agentic system design. Using biopharma as the test case, he breaks down why hardcoded pipelines break down over time, and what composable alternatives require. Read here: linkedin.com/posts/kpeng_th…

.@BenjamineYLiu has raised more than $600M for his AI-native biopharma company - and he's hiring! @formationbio is applying AI to drug development, with a mission to bring new treatments to patients faster and more efficiently. The team is hiring across the board, including: - Director, Brand & Communications - Senior Director or VP, Product - General Manager (Drug Asset Lead) - Principal Data Scientist, Medical Imaging - Data Scientist, Portfolio Optimization - Director, Business Development - Search & Evaluation Full story + list of open roles in thread!

Formation Bio said it has appointed former Biogen research head Michael Ehlers as its chief scientific officer, bringing a seasoned drug and biotech veteran into the AI-focused health startup. bloomberg.com/news/articles/…

Excited to share that Mike Ehlers is joining @formationbio as Chief Scientific Officer and Head of R&D. Over the course of his career as a scientist, drug developer, and investor, Mike has advanced 40+ drugs into the clinic, with approvals spanning Alzheimer's, ALS, MS, hemophilia, and SMA. Welcome to the team, Mike!